Effects of Shenqi Yixin Fang on Myocardial Structure and Cytokines in Doxorubicin-induced Chronic Heart Failure Rats

JIN Juan; CUI Lu; ZOU Guo-liang; LIU Li

doi:10.13422/j.cnki.syfix.2014080128

您当前的位置：

首页 >

文章列表页 >

Effects of Shenqi Yixin Fang on Myocardial Structure and Cytokines in Doxorubicin-induced Chronic Heart Failure Rats

更新时间：2024-01-04

- Effects of Shenqi Yixin Fang on Myocardial Structure and Cytokines in Doxorubicin-induced Chronic Heart Failure Rats
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 8, Pages: 128-132(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfix.2014080128
  CLC：
- Published：2014
- 稿件说明：
移动端阅览
JIN Juan, CUI Lu, ZOU Guo-liang, et al. Effects of Shenqi Yixin Fang on Myocardial Structure and Cytokines in Doxorubicin-induced Chronic Heart Failure Rats[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(8): 128-132.
DOI：

JIN Juan, CUI Lu, ZOU Guo-liang, et al. Effects of Shenqi Yixin Fang on Myocardial Structure and Cytokines in Doxorubicin-induced Chronic Heart Failure Rats[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(8): 128-132. DOI： 10.13422/j.cnki.syfix.2014080128.

摘要

目的：观察参芪益心方对慢性心力衰竭（CHF）大鼠心肌形态、心功能、血浆中血管紧张素Ⅱ（AngⅡ）、肿瘤坏死因子-α（TNF-α）的影响。方法：将90只Wistar雄性大鼠随机平均分为6组：正常对照组、模型组、依那普利对照组、芪苈强心对照组、参芪益心方低剂量（16.96 g·kg-1·d-1）组、高剂量（33.92 g·kg-1·d-1）组。利用阿霉素第l，3，5周，3 mg·kg-1；第2，4，6周，2 mg·kg-1的剂量，每日1次，灌胃4周，观察大鼠的心肌组织形态学及超微结构变化，运用超声心动图检测大鼠左室收缩末期内径（LVSD）、左室舒张末期内径（LVDD）、左室射血分数（EF）、左室短轴缩短率（FS），放免法测定大鼠血浆AngⅡ，TNF-α。结果：经EF，FS提示造模成功，各治疗组LVSD，LVDD，EF，FS均有改善，参芪益心方高剂量组、中药对照组、西药对照组与模型组比较有统计学意义（P<0.05）。各治疗组AngⅡ，TNF-α均有不同程度的降低，与模型组比较有统计学意义（P<0.05）。结论：参芪益心方可以改善CHF大鼠心肌组织形态，抑制心室重构，改善CHF大鼠心功能。

Abstract

Objective: To observe the effect of the Shenqi Yixin Fang on cardiac function

plasma angiotensin Ⅱ(AngⅡ) and tumor necrosis factor-α(TNF-α) of chronic heart failure(CHF) rats. Method: Ninty male Wistar rats were randomly divided into six groups:normal control group

model group

enalapril control group

the Qili Qiangxin control group

the low dose of Shenqi Yixin Fang group(16.96 g·kg-1·d-1)

the high dose of Shenqi Yixin Fang group(33.92 g·kg-1·d-1). Doxorubicin was used to induce CHF models

and the modelling rats were given drug intervention for 4 weeks.The echocardiography was used to measure cardiac function

plasma AngⅡ and TNF-α were measured by radioimmunoassay. Result: In model group the left ventricular end-systolic diameter (LVSD)

left ventricular end-diastolic diameter (LVDD)

left ventricular ejection fraction (EF)

left ventricular fractional were shorten compared with normal control group(P<0.05). In treatment group

these indicators were improved compared with modek group (P <0.05). In treatment groups the plasma AngⅡ/TNF-α levels were reduced compared with the model group (P<0.05). Conclusion: The Shenqi Yixin Fang can improve myocardial tissue morphology

inhibit ventricular remodeling and improve cardiac function in CHF rats.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Qidong Yixin Oral Liquid Activates Nrf2/HO-1 Signaling Pathway to Alleviate Adriamycin-induced Myocardial Injury in Mice

Promotion of Yanghe Decoction-containg Serum for Inhibitory Effect of Doxorubicin on MCF-7 Cell and the Related Mechanism

Effect of Renshen Jianxin Capsule on Neuroendocrine Activation in Rat Congestive Heart Failure Caused by Doxorubicin

Effective Fractions and Mechanism of Descurainiae Semen Lepidii Semen in Chronic Heart Failure Rats

Protective Effect of Berberine on Doxorubicin-induced Myocardial Cell Injury

Related Author

Long-po YANG

Xiao-yu MA

Li-jiao XU

Jing-tao ZOU

Gui-bo SUN

Xiao-bo SUN

Rong-chang CHEN

LIN Hai-hong

Related Institution

Institute of Medicinal Botany, Chinese Academy of Medical Sciences

Tonghua Huaxia Pharmaceutical Co., Ltd.

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰